The hybridoma technology advantage
Antibody reproducibility is key to both research and assay development. Time invested in the production of hybridomas yields key advantages for both researchers and producers alike.
Once stabilized, hybridomas offer unlimited quantities of cost-effective, consistent, homogenized antibody production. Perfect for research, assay development and downstream research, diagnostic and therapeutic uses.
Today, Inotiv delivers: Monoclonal and polyclonal antibody production; Hybridoma development; Immunogenicity immunization; Antibody purification; Mouse antibody production (MAP) testing.
Download the next infographic in the series
Get the third in a series of infographics, charting the history, production strategies and technology challenges faced when producing antibodies for research and manufacture. These resources provide insights collated from Inotiv’s long history in antibody production, with quick reference production strategies and useful reminders of the challenges commonly faced by researchers and production engineers.
